Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.43.6 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.27NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.43.9 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XUNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.3 (Omicron)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.1.16.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.372NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.425NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.5.55NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HH.8.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FL.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FM.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FK.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.7.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.8.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EU.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.14NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.21NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EJ.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BM.1.1.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.123.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.9.2.2 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EW.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.1.37NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1.4.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EW.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBF.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBPNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.22NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.36NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.37NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.10NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.21NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BN.1.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.277NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-1906.48Singapore
AY.28 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.272NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.371NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AA.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.353NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.407NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AA.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.160.13NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used